Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis

Bernadette A. M. Heemskerk-Gerritsen, Matti A. Rookus, Cora M. Aalfs, Margreet G. E. M. Ausems, Johanna M. Collee, Liesbeth Jansen, C. Marleen Kets, Kristien B. M. I. Keymeulen, Linetta B. Koppert, Hanne E. J. Meijers-Heijboer, Thea M. Mooij, Rob A. E. M. Tollenaar, Hans F. A. Vasen, Maartje J. Hooning, Caroline Seynaeve*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

95 Citations (Web of Science)


Data on survival of BRCA1/2-associated primary breast cancer (PBC) patients who opt for subsequent contralateral risk-reducing mastectomy (CRRM) are scarce and inconsistent. We examined the efficacy of CRRM on overall survival in mutation carriers with a history of PBC. From a Dutch multicentre cohort, we selected 583 BRCA-associated PBC patients, being diagnosed between 1980 and 2011. Over time, 242 patients (42%) underwent CRRM and 341 patients (58%) remained under surveillance. Survival analyses were performed using Cox models, with CRRM as a time-dependent covariate. The median follow-up after PBC diagnosis was 11.4 years. In the CRRM group, four patients developed contralateral breast cancer (2%), against 64 patients (19%) in the surveillance group (p
Original languageEnglish
Pages (from-to)668-677
JournalInternational Journal of Cancer
Issue number3
Publication statusPublished - 15 Feb 2015


  • BRCA1
  • 2
  • breast cancer
  • prevention
  • contralateral risk-reducing mastectomy
  • survival

Cite this